Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Bioventus (BVS) Receivables - Net (2020 - 2026)

Bioventus filings provide 6 years of Receivables - Net readings, the most recent being $131.2 million for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 2.99% to $131.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $131.2 million, a 2.99% increase, with the full-year FY2025 number at $131.2 million, up 2.99% from a year prior.
  • Receivables - Net hit $131.2 million in Q4 2025 for Bioventus, up from $130.4 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $143.0 million in Q3 2022 to a low of $89.5 million in Q2 2021.
  • Median Receivables - Net over the past 5 years was $125.7 million (2023), compared with a mean of $124.0 million.
  • Biggest five-year swings in Receivables - Net: skyrocketed 40.17% in 2022 and later fell 18.21% in 2023.
  • Bioventus' Receivables - Net stood at $125.0 million in 2021, then grew by 9.07% to $136.3 million in 2022, then fell by 6.81% to $127.0 million in 2023, then grew by 0.3% to $127.4 million in 2024, then grew by 2.99% to $131.2 million in 2025.
  • The last three reported values for Receivables - Net were $131.2 million (Q4 2025), $130.4 million (Q3 2025), and $135.3 million (Q2 2025) per Business Quant data.